Exxon Mobil (XOM) stock ticks up as filing flags up to $1.2 bln Q4 upstream hit
9 January 2026
1 min read

Exxon Mobil (XOM) stock ticks up as filing flags up to $1.2 bln Q4 upstream hit

NEW YORK, Jan 9, 2026, 11:39 EST — Regular session

Exxon Mobil (XOM) shares rose 0.6% to $123.63 on Friday after the oil major said lower crude prices could cut fourth-quarter upstream earnings — its oil and gas production business — by about $800 million to $1.2 billion. It also said stronger refining margins, the gap between crude costs and fuel prices, could lift earnings by $300 million to $700 million, while restructuring charges may shave about $200 million. Analysts expect adjusted earnings of $1.66 per share; “many brokers, including us, have yet to mark to market,” Scotiabank analysts wrote. 1

The filing lands just ahead of a wave of fourth-quarter reports from big energy producers, and it sets the opening range for how much the late-2025 slide in crude and gas prices may show up in profits. For traders, the numbers matter less as a forecast than as a reset of assumptions.

Oil prices climbed again on Friday on supply worries, keeping the broader energy tape firm; Brent was up 0.8% at $62.49 a barrel and U.S. crude gained 0.9% to $58.27. “Iran protests seem to be gathering momentum, leading the market to worry about disruptions,” Ole Hansen, head of commodity analysis at Saxo Bank, said. Chevron shares rose 1.4%. 2

Exxon also popped up in overseas exploration news this week. Turkey’s state oil company TPAO and Exxon’s Esso Exploration International Limited unit signed a memorandum of understanding covering new exploration areas in the Black Sea and the Mediterranean, Energy Minister Alparslan Bayraktar said, calling it a step to “pave the way for new discoveries.” The ministry statement gave no spending figure or drilling timetable. 3

Exxon’s quarterly “earnings considerations” updates have become a quick read for investors trying to separate price swings from what management can control — volumes, maintenance and costs. This quarter, the production hit is doing the talking, even with refining offering some cover.

But the setup can turn fast. A pullback in crude, weaker fuel demand or a fresh squeeze in gas prices could drag results below current forecasts and weigh on what Exxon says about shareholder returns and spending.

Investors now look to Exxon’s fourth-quarter report on Jan. 30, when the company expects to post results at about 5:30 a.m. Central time on its website and in an SEC filing. The focus will be on how much refining offsets the upstream hit, and what Exxon says about costs and returns in 2026. 4

Stock Market Today

P&G stock ends week near $159 as rate-cut talk returns — what investors watch next

P&G stock ends week near $159 as rate-cut talk returns — what investors watch next

7 February 2026
New York, Feb 7, 2026, 13:56 EST — Market closed. Procter & Gamble shares closed Friday up about 0.4% at $159.17, after trading between $158.01 and $159.99. The stock is still well below the top of its 52-week range, a reminder that the move has been steady rather than sharp. 1 With U.S. markets shut on Saturday, attention swings back to rates and the growth outlook before Monday’s open. San Francisco Fed President Mary Daly told Reuters she sees “one or two” rate cuts as possible this year if the labor market weakens further, describing workers as “walking a knife’s
Real estate stocks rise as rate-cut bets return; XLRE ends at $41.99 ahead of payrolls and CPI

Real estate stocks rise as rate-cut bets return; XLRE ends at $41.99 ahead of payrolls and CPI

7 February 2026
U.S. real estate stocks rose Friday, with XLRE up 1.8% to $41.99 and VNQ and IYR each gaining 1.6%. The Dow closed above 50,000 for the first time as the 10-year Treasury yield ended at 4.206%. Bank of America downgraded Public Storage and Extra Space Storage, citing weak housing turnover and high borrowing costs. The delayed January jobs report is set for Feb. 11, with CPI due Feb. 13.
CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026
Previous Story

CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

Figure Technology Solutions stock slips after a $62 target hike — what traders watch nextFigureFigure Technology Solutions stock slips after a $62 target hike — what traders watch next
Next Story

Figure Technology Solutions stock slips after a $62 target hike — what traders watch nextFigureFigure Technology Solutions stock slips after a $62 target hike — what traders watch next

Go toTop